Tests psilocybin with trazodone for depression that has not responded to treatment
Tests psilocybin plus trazodone against placebo in adults with treatment-resistant depression.
Key facts
- Who runs it
- Groupe Hospitalier Universitaire Paris Psychiatrie & Neuroscience
- Where
- Paris, FranceSee the site
- Trial code
- Registry title
- Efficacy of psilocybin and trazodone combination in treatment-resistant depression: a randomized controlled proof-of-concept study (PSILOTRAZ)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 112 people, planned
- Started
- 30 Jun 2026
- Expected to end
- 14 Apr 2029
- Type of study
- Interventional
- Record updated
- 18 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose major depression has not improved after at least two antidepressant medicines. It tests psilocybin with trazodone against placebo, with psychotherapy support.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Major depressive episode without psychotic features (DSM-5), with a MADRS score of 20 or more. The depression must be treatment-resistant: no response to at least two antidepressant medicines at an adequate dose for 6 weeks.
- Earlier treatment
- Must have had at least two antidepressant medicines that did not work. Cannot have used psychedelics (psilocybin, lysergic acid, ayahuasca, mescaline) during the current episode.
Main reasons for not taking part
- Bipolar disorder, schizophrenia or psychosis, or a personal or family history of psychotic disorder
- Significant suicide risk
- Pregnancy or breastfeeding
- Heart or blood vessel problems, such as heart attack, stroke, heart rhythm disorder or uncontrolled high blood pressure
- Alcohol or substance use disorder in the past 12 months, or epilepsy
The registry criteria, word for word
Show all 34 criteriaShow less
Who can take part
- Age ≥ 18 years old
- Patient with major depressive episode without psychotic features according to DSM-5 criteria
- MADRS score ≥ 20
- Treatment-resistant depressive episode, i.e. failure to respond to at least two lines of antidepressant medication at an adequate dose and for a sufficient period of time (6 weeks according to the MGH-ATRQ)
- Free, informed and prior written consent of the patient
- Persons covered by the social security system
Who cannot take part
- Contraindications to MRI: Implants (mechanical or electronic: cochlear implants, pacemakers, infusion pumps, magnetic clips, etc.) incompatible with the magnetic field; Metallic foreign bodies in the eye or nervous system; Claustrophobia; Non-removable dental removable braces
- Treatment with buprenorphine or opioids
- Patient with a psychiatric decompensation following a previous use of psychedelic substance like LSD
- Concomitant therapies
- Bipolar disorder
- Uncontrolled thyroid disorder
- Epilepsy
- Persons deprived of their liberty by judicial or administrative decision, persons under compulsory psychiatric care
- Parkinson’s disease treated by selegiline or levodopa
- HIV treated by ritonavir and indinavir
- Active infection treated by erythromycin
- Fungal infection treated by ketoconazole and itraconazole
- Personal or family history of psychotic disorder
- History of personality disorder
- Post-traumatic stress disorder, obsessive-compulsive disorder, eating disorders
- Alcohol or substance use disorder in past 12 months or positive urine toxins at time of assessment
- Uncontrolled diabetes
- Cardiovascular history (myocardial infarction, stroke, heart rhythm disorder, uncontrolled hypertension, QT interval prolongation, tachycardia and poor cardiovascular health)
- Significant suicide risk, as defined by: (a) suicidal ideation as indicated by items 4 or 5 on the C-SSRS within the past six months, at Screening, during the Screening Period, or at Baseline (b) demonstrating suicidal behaviors in the past six months, or; (c) clinical assessment of significant suicidal risk or risk of self-injury during participant interview
- 5-HT2A antagonist treatment (including quetiapine, olanzapine, aripiprazole)
- Lithium treatment
- Use of psychedelics (psilocybin, lysergic acid, ayahuasca, mescaline and derivatives) during current episode
- Persons under legal protection or unable to give consent
- Any clinical event that, in the opinion of the investigator, may interfere with the interpretation of study results or constitute a health risk to the participant if he or she participates in the study
- Schizophrenia and psychosis
- Legal status
- Other: Any clinical manifestation which, in the opinion of the investigator, may interfere with the interpretation of study results or constitute a health risk to the participant if he or she participates in the study
- Pregnancy and breastfeeding women
Where in France
- GHU St Anne Psychiatrie et NeurosciencesParis, FranceTaking people
About the trial
What the trial wants to find out
To evaluate the efficacy of a single administration of the combination of psilocybin 25 mg + trazodone 30 mg (compared to placebo), administered with psychotherapeutic support in adult patients with TRD, in improving symptoms of depression at 1 month.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Efficacy of psilocybin and trazodone combination in treatment-resistant depression: a randomized controlled proof-of-concept study (PSILOTRAZ)
- Plain-language title
- Tests psilocybin with trazodone for depression that has not responded to treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 18 May 2026